SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure

Recent studies have shown impressive cardiovascular health benefits in individuals treated with SGLT2 inhibitors (SGLT2i) regardless of diabetic status. The underlying mechanisms driving these benefits are not well understood. Recently in Circulation, Griffin et al. (2020) reported the first human s...

Full description

Saved in:
Bibliographic Details
Published inCell metabolism Vol. 32; no. 1; pp. 13 - 14
Main Authors Verma, Ashish, Patel, Ankit B., Waikar, Sushrut S.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 07.07.2020
Online AccessGet full text
ISSN1550-4131
1932-7420
1932-7420
DOI10.1016/j.cmet.2020.06.014

Cover

More Information
Summary:Recent studies have shown impressive cardiovascular health benefits in individuals treated with SGLT2 inhibitors (SGLT2i) regardless of diabetic status. The underlying mechanisms driving these benefits are not well understood. Recently in Circulation, Griffin et al. (2020) reported the first human study investigating the diuretic effect of empagliflozin. Recent studies have shown impressive cardiovascular health benefits in individuals treated with SGLT2 inhibitors (SGLT2i) regardless of diabetic status. The underlying mechanisms driving these benefits are not well understood. Recently in Circulation, Griffin et al. reported the first human study investigating the diuretic effect of empagliflozin.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:1550-4131
1932-7420
1932-7420
DOI:10.1016/j.cmet.2020.06.014